Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer

Clinical Colorectal Cancer

Volumn 13, Issue 3, 2014, Pages 135-144

  Lee, James J ^a   Chu, Edward ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Bevacizumab; Regorafenib; VEGF; Ziv aflibercept

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; AFLIBERCEPT; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARBANILAMIDE DERIVATIVE; DEOXYCYTIDINE; HYBRID PROTEIN; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; PLATINUM COMPLEX; PYRIDINE DERIVATIVE; RAS PROTEIN; REGORAFENIB; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

AGE; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG APPROVAL; HUMAN; MAINTENANCE THERAPY; METASTATIC COLORECTAL CANCER; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; DRUG EFFECTS; GENETICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETREATMENT; SECONDARY; SIGNAL TRANSDUCTION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; LEUCOVORIN; ORGANOPLATINUM COMPOUNDS; PHENYLUREA COMPOUNDS; PROTO-ONCOGENE PROTEINS; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RAS PROTEINS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETREATMENT; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84908155926     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2014.02.001     Document Type: Review

References (70)

1. R. Siegel, J. Ma, and Z. Zou Cancer statistics, 2014 CA Cancer J Clin 64 2014 9 29
2. E. Chu An update on the current and emerging targeted agents in metastatic colorectal cancer Clin Colorectal Cancer 11 2012 1 13
3. C. Tournigand, T. Andre, and E. Achille FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 2004 229 237
4. G. Colucci, V. Gebbia, and G. Paoletti Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale J Clin Oncol 23 2005 4866 4875
5. R.M. Goldberg, D.J. Sargent, and R.F. Morton A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J Clin Oncol 22 2004 23 30
6. L.B. Saltz, J.V. Cox, and C. Blanke Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group N Engl J Med 343 2000 905 914
7. J.Y. Douillard, D. Cunningham, and A.D. Roth Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial Lancet 355 2000 1041 1047
8. N. Ferrara Vascular endothelial growth factor: basic science and clinical progress Endocr Rev 25 2004 581 611
9. Q.S. Chu Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors Expert Opin Biol Ther 9 2009 263 271
10. T. Veikkola, and K. Alitalo VEGFs, receptors and angiogenesis Semin Cancer Biol 9 1999 211 220
11. L.G. Presta, H. Chen, and S.J. O'Connor Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders Cancer Res 57 1997 4593 4599
12. N. Ferrara, K.J. Hillan, and W. Novotny Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy Biochem Biophys Res Commun 333 2005 328 335
13. S.M. Wilhelm, J. Dumas, and L. Adnane Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity Int J Cancer 129 2011 245 255
14. A. Grothey, E. Van Cutsem, and A. Sobrero Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial Lancet 381 2013 303 312
15. Stivarga (regorafenib) [package insert]: Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc; 2012.
16. L. Yu, X.H. Liang, and N. Ferrara Comparing protein VEGF inhibitors: in vitro biological studies Biochem Biophys Res Commun 408 2011 276 281
17. X. Li, C. Lee, and Z. Tang VEGF-B: a survival, or an angiogenic factor? Cell Adh Migr 3 2009 322 327
18. F. Zhang, Z. Tang, and X. Hou VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis Proc Natl Acad Sci U S A 106 2009 6152 6157
19. J. Holash, S. Davis, and N. Papadopoulos VEGF-Trap: a VEGF blocker with potent antitumor effects Proc Natl Acad Sci U S A 99 2002 11393 11398
20. C. Fischer, B. Jonckx, and M. Mazzone Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels Cell 131 2007 463 475
21. S. Loges, T. Schmidt, and P. Carmeliet "Antimyeloangiogenic" therapy for cancer by inhibiting PlGF Clin Cancer Res 15 2009 3648 3653
22. N. Papadopoulos, J. Martin, and Q. Ruan Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab Angiogenesis 15 2012 171 185
23. Schmieder R, Hoffmann J, Becker M, et al. Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer. Int J Cancer, Published online December 17, 2013; http://dx.doi.org/10.1002/ijc.28669.
24. L. Abou-Elkacem, S. Arns, and G. Brix Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model Mol Cancer Ther 12 2013 1322 1331
25. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
26. L.B. Saltz, S. Clarke, and E. Diaz-Rubio Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2008 2013 2019
27. E. Van Cutsem, F. Rivera, and S. Berry Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study Ann Oncol 20 2009 1842 1847
28. F. Kabbinavar, H.I. Hurwitz, and L. Fehrenbacher Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 21 2003 60 65
29. A.L. Cohn, T. Bekaii-Saab, and J.C. Bendell Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP) J Clin Oncol 28 2010 (abstract 3596)
30. A. Grothey, M.M. Sugrue, and D.M. Purdie Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE) J Clin Oncol 26 2008 5326 5334
31. J. Cassidy, S. Clarke, and E. Diaz-Rubio Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer J Clin Oncol 26 2008 2006 2012
32. J. Cassidy, S. Clarke, and E. Diaz-Rubio XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results Br J Cancer 105 2011 58 64
33. H.S. Hochster, L.L. Hart, and R.K. Ramanathan Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study J Clin Oncol 26 2008 3523 3529
34. C.S. Fuchs, J. Marshall, and E. Mitchell Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study J Clin Oncol 25 2007 4779 4786
35. C.S. Fuchs, J. Marshall, and J. Barrueco Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study J Clin Oncol 26 2008 689 690
36. C. Pericay, G. Folprecht, and M. Saunders Phase 2 randomized, noncomparative open-label study of aflibercept and modified FOLFOX6 in the first line treatment of metastatic colorectal cancer (AFFIRM) Ann Oncol 2012 23 (abstract O-0024)
37. M. Sehl, R. Sawhney, and A. Naeim Physiologic aspects of aging: impact on cancer management and decision making, part II Cancer J 11 2005 461 473
38. R. Sawhney, M. Sehl, and A. Naeim Physiologic aspects of aging: impact on cancer management and decision making, part I Cancer J 11 2005 449 460
39. D. Cunningham, I. Lang, and E. Marcuello Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial Lancet Oncol 14 2013 1077 1085
40. E. Diaz-Rubio, A. Gomez-Espana, and B. Massuti First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study Oncologist 17 2012 15 25
41. M. Koopman, L. Simkens, and A. May Final results and subgroup analyses of the phase 3 CAIRO3 study: maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC) ASCO Meeting Abstracts 2014 32 (abstract LBA388)
42. M. Koopman, L.H. Simkens, and A.J. Ten Tije Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): the phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG) ASCO Meeting Abstracts 2013 31 (abstract 3502)
43. V. Heinemann, L. Fischer von Weikersthal, and T. Decker Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3) ASCO Meeting Abstracts 2013 31 (abstract LBA3506)
44. S. Stintzing, A. Jung, and L. Rossius Mutations within the EGFR signaling pathway: influence on efficacy in FIRE-3-a randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients ASCO Meeting Abstracts 2014 32 (abstract 445)
45. B.J. Giantonio, P.J. Catalano, and N.J. Meropol Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25 2007 1539 1544
46. J. Bennouna, J. Sastre, and D. Arnold Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial Lancet Oncol 14 2013 29 37
47. E. Van Cutsem, J. Tabernero, and R. Lakomy Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen J Clin Oncol 30 2012 3499 3506
48. S. Tejpar, H. Prenen, and M. Mazzone Overcoming resistance to antiangiogenic therapies Oncologist 17 2012 1039 1050
49. G. Bergers, and D. Hanahan Modes of resistance to anti-angiogenic therapy Nat Rev Cancer 8 2008 592 603
50. S. Kopetz, P.M. Hoff, and J.S. Morris Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance J Clin Oncol 28 2010 453 459
51. C.J. Allegra, R. Lakomy, and J. Tabernero Effects of prior bevacizumab (B) use on outcomes from the VELOUR study: a phase III study of aflibercept (Afl) and FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin regimen J Clin Oncol 30 2012 (abstract 3505)
52. E. Van Cutsem, D. Ferry, and R. Lakomy Aflibercept/FOLFIRI vs placebo/FOLFIRI in metastatic colorectal cancer: post-hoc analysis of survival by prior bevacizumab use subsequent to exclusion of patients who had recurrence during or within 6 months of completing adjvuant oxaliplatin-based therapy European Cancer Congress 2013 (abstract 2260)
53. I. Chau, F. Joulain, and S. Iqbal VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer (mcrc) treated with aflibercept and FOLFIRI Ann Oncol 24 2013 (abstract iv91)
54. Zaltrap (ziv-aflibercept) [package insert]: Bridgewater, NJ: Sanofi-aventis U.S. LLC; 2012.
55. D. Ferry, P. Ruff, and R. Lakomy Time course of adverse events in the VELOUR trial Ann Oncol 24 2013 (abstract iv36)
56. D. Ferry, T.W. Kim, and T.K. Guren On-treatment progression-free survival analysis of ziv-aflibercept/FOLFIRI treatment within 28 days of end of treatment in metastatic colorectal cancer: updated efficacy results from the VELOUR study J Clin Oncol 31 2013 (abstract 3573)
57. E.P. Mitchell, M.J. Guarino, and M.L. Andria North American (NA) subgroup results from VELOUR: ziv-aflibercept versus placebo plus FOLFIRI in mCRC that is resistant to or has progressed after an oxaliplatin-containing regimen J Clin Oncol 31 2013 (abstract e14528)
58. P. Ruff, R. Lakomy, and J. Prausova Analysis of overall survival and safety during the course of the phase III VELOUR trial comparing FOLFIRI and aflibercept or placebo in patients with mCRC that progressed on prior oxaliplatin treatment J Clin Oncol 31 2013 (abstract 451)
59. J. Yao, X. Wu, and G. Zhuang Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy Proc Natl Acad Sci U S A 108 2011 11590 11595
60. R.N. Kaplan, R.D. Riba, and S. Zacharoulis VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche Nature 438 2005 820 827
61. D. Lambrechts, H.J. Lenz, and S. de Haas Markers of response for the antiangiogenic agent bevacizumab J Clin Oncol 31 2013 1219 1230
62. A.J. Weickhardt, D. Williams, and C. Lee Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): analysis of the phase III MAX study J Clin Oncol 29 2011 (abstract 3531)
63. O. Christensen, M. Buechert, and U. Fasol Analysis of plasma biomarkers, Mri, and Kras mutations in patients (Pts) with advanced colorectal carcinoma (Crc) treated with the multikinase inhibitor regorafenib Ann Oncol 21 2010 (abstract 200-1)
64. J. Spratlin Ramucirumab (IMC-1121B): monoclonal antibody inhibition of vascular endothelial growth factor receptor-2 Curr Oncol Rep 13 2011 97 102
65. J.L. Spratlin, R.B. Cohen, and M. Eadens Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 J Clin Oncol 28 2010 780 787
66. R. Garcia-Carbonero, F. Rivera, and J. Maurel A phase II, open-label study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC) ASCO Meeting Abstracts 2012 30 (abstract 533)
67. ClinicalTrials.gov [Web site]. A randomized, double-blind, multicenter phase 3 study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progressive during or following first-line combination therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. Available at: http://clinicaltrials.gov/show/NCT01183780. Accessed: July 3, 2013.
68. Y. Wu, Z. Zhong, and J. Huber Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer Clin Cancer Res 12 2006 6573 6584
69. Lorusso PM, Krishnamurthi S, Youssoufian H, et al. Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a phase 1 study. Invest New Drugs, 2014; 32:303-11.
70. ClinicalTrials.gov [Web site]. An open-label, multicenter, randomized phase 2 study evaluating the safety and efficacy of 5 FU/FA and oxaliplatin (modified FOLFOX 6) in combination with IMC-1121B or IMC-18F1 or without investigational therapy as second line therapy in patients with metastatic colorectal cancer following disease progression on first line irinotecan-based therapy. Available at: http://clinicaltrials.gov/show/NCT01111604. Accessed: July 3, 2013.